AMICUS THERAPEUTICS, INC. 8-K

What Happened

• Amicus Therapeutics filed an 8-K (Items 2.02 and 7.01) providing preliminary, unaudited financial information it gave to BioMarin Pharmaceutical Inc. for inclusion in BioMarin’s preliminary offering memorandum dated January 26, 2026. The data relate to Amicus’ financial condition and 2025 product revenues in connection with the proposed acquisition by BioMarin.
• Key figures reported: as of December 31, 2025, Amicus estimates approximately $294 million in cash, cash equivalents, and marketable securities; for the year ended December 31, 2025, estimated total net product revenues were about $634 million (approximately $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®). These are preliminary, unaudited, and subject to change.

Key Details

• Cash and equivalents (12/31/2025): ~ $294 million (unaudited, preliminary).
• 2025 total net product revenue: ~ $634 million (unaudited, preliminary).
• Revenue by product: Galafold® ~ $522 million; Pombiliti® + Opfolda® ~ $112 million.
• Accounting/audit caveats: Amicus has not completed a full accounting close for any period after Sept 30, 2025, and Ernst & Young LLP has not audited or reviewed these preliminary estimates.

Why It Matters

• These preliminary results give investors and counterparties a snapshot of Amicus’ size and revenue mix ahead of the proposed acquisition by BioMarin and BioMarin’s related debt offering to fund the deal. Revenue breakdown highlights Galafold as the largest contributor.
• Important caution: the figures are unaudited and management-prepared; they may change during normal closing procedures and have not been audited or reviewed by Amicus’ independent auditor. Investors should treat them as estimates and not a substitute for audited financial statements, and should review Amicus’ filings for the stated “Risk Factors” and “Forward‑Looking Statements.”